LQDA

SEC source: 0001209191-22-009600 · doc5.xml · nonDerivative · entry 1

Manning Paul B · CIK 0001494695 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

F1 · ownership.nature: The securities are held by PBM Capital Finance, LLC ("PBM"). The Reporting Person is the manager and sole beneficial owner of PBM.

SEC source: 0001104659-21-069361 · tm2116961-1_4seq1.xml · nonDerivative · entry 3

Schundler Russell · CIK 0001854414 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 14,500

F1 · balance_after: The reporting person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein.

SEC source: 0001104659-21-069361 · tm2116961-1_4seq1.xml · nonDerivative · entry 2

Schundler Russell · CIK 0001854414 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 102,680

SEC source: 0001104659-21-069361 · tm2116961-1_4seq1.xml · nonDerivative · entry 1

Schundler Russell · CIK 0001854414 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 61,053

SEC source: 0001104659-21-050550 · tm2113044-2_4seq1.xml · nonDerivative · entry 1

Manning Paul B · CIK 0001494695 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 737,646

F1 · ownership.nature: The securities are held by PD Joint Holdings, LLC Series 2016-A ("PD"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC ("Tiger Lily"), the manager of PD, and has shared voting and investment power with respect to the shares held by PD.

SEC source: 0001104659-21-050547 · tm2113044-1_4seq1.xml · nonDerivative · entry 1

JEFFS ROGER · CIK 0001231615 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 111,706

SEC source: 0000902664-21-002335 · ownership.xml · derivative · entry 2

JOHNSON DAVID EDWARD · CIK 0001785557 · Director · 10% owner · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,132

Underlying: Common Stock · 16,132 shares

Expires 2031-04-13

F2 · derivative.exercise_date: The stock option vests in quarterly installments, with 4,840 shares of Common Stock vesting on June 30, 2021 and 5,646 shares of Common Stock vesting on each of September 30, 2021 and December 31, 2021.

SEC source: 0000902664-21-002335 · ownership.xml · derivative · entry 1

JOHNSON DAVID EDWARD · CIK 0001785557 · Director · 10% owner · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2031-04-13

F1 · derivative.exercise_date: The stock option vests in 36 equal monthly installments, becoming fully vested on April 13, 2024.

SEC source: 0001104659-21-044804 · tm2111407-2_4seq1.xml · derivative · entry 1

Schundler Russell · CIK 0001854414 · Director · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2031-03-29

F1 · derivative.exercise_date: The option vests over a four-year period with 25% of the shares of common stock underlying the option vesting on the one-year anniversary of the grant date and the remaining 75% of the shares of common stock underlying the option vesting in equal monthly installments thereafter, becoming fully vested on March 29, 2025.

SEC source: 0001104659-21-042439 · tm2111007d7_4seq1.xml · derivative · entry 1

SINGH RAMAN · CIK 0001747589 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,524

Underlying: Common Stock · 25,524 shares

Expires 2031-03-24

F1 · derivative.exercise_date: The option vests quarterly during 2021, with 25% of the option shares vesting on the date of grant, and 25% of the option shares vesting on each of June 30, 2021, September 30, 2021 and December 31, 2021, becoming fully vested on December 31, 2021.

SEC source: 0001104659-21-042434 · tm2111007-5_4seq1.xml · derivative · entry 1

Manning Paul B · CIK 0001494695 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,385

Underlying: Common Stock · 21,385 shares

Expires 2031-03-24

F1 · derivative.exercise_date: The option vests quarterly during 2021, with 25% of the option shares vesting on the date of grant, and 25% of the option shares vesting on each of June 30, 2021, September 30, 2021 and December 31, 2021, becoming fully vested on December 31, 2021.

SEC source: 0001104659-21-042431 · tm2111007-4_4seq1.xml · derivative · entry 1

Kirsch Arthur S · CIK 0001290976 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,390

Underlying: Common Stock · 41,390 shares

Expires 2031-03-24

F1 · derivative.exercise_date: The option vests quarterly during 2021, with 25% of the option shares vesting on the date of grant, and 25% of the option shares vesting on each of June 30, 2021, September 30, 2021 and December 31, 2021, becoming fully vested on December 31, 2021.

SEC source: 0001104659-21-042428 · tm2111007-3_4seq1.xml · derivative · entry 1

JEFFS ROGER · CIK 0001231615 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,353

Underlying: Common Stock · 30,353 shares

Expires 2031-03-24

F1 · derivative.exercise_date: The option vests quarterly during 2021, with 25% of the option shares vesting on the date of grant, and 25% of the option shares vesting on each of June 30, 2021, September 30, 2021 and December 31, 2021, becoming fully vested on December 31, 2021.

SEC source: 0001104659-21-042420 · tm2111007-1_4seq1.xml · derivative · entry 1

Bloch Stephen M · CIK 0001400308 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,187

Underlying: Common Stock · 55,187 shares

Expires 2031-03-24

F1 · derivative.exercise_date: The option vests quarterly during 2021, with 25% of the option shares vesting on the date of grant, and 25% of the option shares vesting on each of June 30, 2021, September 30, 2021 and December 31, 2021, becoming fully vested on December 31, 2021.

SEC source: 0001104659-21-042423 · tm2111007-2_4seq1.xml · derivative · entry 1

Horobin Joanna · CIK 0001560959 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,872

Underlying: Common Stock · 35,872 shares

Expires 2031-03-24

F1 · derivative.exercise_date: The option vests quarterly during 2021, with 25% of the option shares vesting on the date of grant, and 25% of the option shares vesting on each of June 30, 2021, September 30, 2021 and December 31, 2021, becoming fully vested on December 31, 2021.

SEC source: 0001104659-21-042437 · tm2111007-6_4seq1.xml · derivative · entry 1

Rielly-Gauvin Katherine · CIK 0001791718 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,182

Underlying: Common Stock · 35,182 shares

Expires 2031-03-24

F1 · derivative.exercise_date: The option vests quarterly during 2021, with 25% of the option shares vesting on the date of grant, and 25% of the option shares vesting on each of June 30, 2021, September 30, 2021 and December 31, 2021, becoming fully vested on December 31, 2021.

SEC source: 0001578563-21-000008 · primary_doc.xml · nonDerivative · entry 1

Eshelman Ventures, LLC · CIK 0001706673 · 10% owner

ESHELMAN FREDRIC N · CIK 0001033409 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,601,210

F1 · price: This transaction was executed in multiple trades at prices ranging from $2.94 to $3.3650. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the trades were effected.

F2 · ownership.direct: The securities reported as directly beneficially owned by the Reporting Person may be deemed to be indirectly beneficially owned by Dr. Eshelman, who is the manager of the Reporting Person.

SEC source: 0001578563-21-000007 · primary_doc.xml · nonDerivative · entry 2

Eshelman Ventures, LLC · CIK 0001706673 · 10% owner

ESHELMAN FREDRIC N · CIK 0001033409 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,363,372

F3 · price: This transaction was executed in multiple trades at prices ranging from $2.90 to $3.05. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the trades were effected.

F2 · ownership.direct: The securities reported as directly beneficially owned by the Reporting Person may be deemed to be indirectly beneficially owned by Dr. Eshelman, who is the manager of the Reporting Person.

SEC source: 0001578563-21-000007 · primary_doc.xml · nonDerivative · entry 1

Eshelman Ventures, LLC · CIK 0001706673 · 10% owner

ESHELMAN FREDRIC N · CIK 0001033409 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,082,659

F1 · price: This transaction was executed in multiple trades at prices ranging from $2.90 to $3.01. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the trades were effected.

F2 · ownership.direct: The securities reported as directly beneficially owned by the Reporting Person may be deemed to be indirectly beneficially owned by Dr. Eshelman, who is the manager of the Reporting Person.

SEC source: 0001578563-21-000006 · primary_doc.xml · nonDerivative · entry 1

Eshelman Ventures, LLC · CIK 0001706673 · 10% owner

ESHELMAN FREDRIC N · CIK 0001033409 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,582,659

F1 · price: This transaction was executed in multiple trades at prices ranging from $2.90 to $3.01. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the trades were effected.

F2 · ownership.direct: The securities reported as directly beneficially owned by the Reporting Person may be deemed to be indirectly beneficially owned by Dr. Eshelman, who is the manager of the Reporting Person.

SEC source: 0001578563-21-000005 · primary_doc.xml · nonDerivative · entry 2

Eshelman Ventures, LLC · CIK 0001706673 · 10% owner

ESHELMAN FREDRIC N · CIK 0001033409 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,910,909

F3 · price: This transaction was executed in multiple trades at prices ranging from $2.95 to $2.99. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the trades were effected.

F2 · ownership.direct: The securities reported as directly beneficially owned by the Reporting Person may be deemed to be indirectly beneficially owned by Dr. Eshelman, who is the manager of the Reporting Person.

SEC source: 0001104659-21-005981 · tm213622-1_4seq1.xml · derivative · entry 2

Shah Tushar · CIK 0001487632 · CMO and Head of R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,250

Underlying: Common Stock · 51,250 shares

Expires not disclosed

F2 · derivative.exercise_date: The performance stock units (PSUs) vest in full upon tentative approval by the U.S. Food and Drug Administration of the New Drug Application for LIQ861. Each PSU represents a contingent right to receive one share of common stock of the issuer.

F2 · derivative.expiration_date: The performance stock units (PSUs) vest in full upon tentative approval by the U.S. Food and Drug Administration of the New Drug Application for LIQ861. Each PSU represents a contingent right to receive one share of common stock of the issuer.

SEC source: 0001104659-21-005981 · tm213622-1_4seq1.xml · derivative · entry 1

Shah Tushar · CIK 0001487632 · CMO and Head of R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 102,500

Underlying: Common Stock · 102,500 shares

Expires 2031-01-19

F1 · derivative.exercise_date: The option vests in equal monthly installments over a four-year period, becoming fully vested on January 19, 2025.

SEC source: 0001104659-21-005984 · tm213622d3_4seq1.xml · derivative · entry 2

Lippe Robert A · CIK 0001600757 · Chief Operations Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,250

Underlying: Common Stock · 51,250 shares

Expires not disclosed

F2 · derivative.exercise_date: The performance stock units (PSUs) vest in full upon tentative approval by the U.S. Food and Drug Administration of the New Drug Application for LIQ861. Each PSU represents a contingent right to receive one share of common stock of the issuer.

F2 · derivative.expiration_date: The performance stock units (PSUs) vest in full upon tentative approval by the U.S. Food and Drug Administration of the New Drug Application for LIQ861. Each PSU represents a contingent right to receive one share of common stock of the issuer.

SEC source: 0001104659-21-005984 · tm213622d3_4seq1.xml · derivative · entry 1

Lippe Robert A · CIK 0001600757 · Chief Operations Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 102,500

Underlying: Common Stock · 102,500 shares

Expires 2031-01-19

F1 · derivative.exercise_date: The option vests in equal monthly installments over a four-year period, becoming fully vested on January 19, 2025.

SEC source: 0001104659-21-005988 · tm213622-5_4seq1.xml · derivative · entry 2

Kaseta Michael · CIK 0001724346 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,250

Underlying: Common Stock · 9,250 shares

Expires not disclosed

F2 · derivative.exercise_date: The performance stock units (PSUs) vest in full upon tentative approval by the U.S. Food and Drug Administration of the New Drug Application for LIQ861. Each PSU represents a contingent right to receive one share of common stock of the issuer.

F2 · derivative.expiration_date: The performance stock units (PSUs) vest in full upon tentative approval by the U.S. Food and Drug Administration of the New Drug Application for LIQ861. Each PSU represents a contingent right to receive one share of common stock of the issuer.

SEC source: 0001104659-21-005988 · tm213622-5_4seq1.xml · derivative · entry 1

Kaseta Michael · CIK 0001724346 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,500

Underlying: Common Stock · 18,500 shares

Expires 2031-01-19

F1 · derivative.exercise_date: The option vests in equal monthly installments over a four-year period, becoming fully vested on January 19, 2025.

SEC source: 0001104659-21-005987 · tm213622-4_4seq1.xml · derivative · entry 2

Krawchick Florina · CIK 0001783634 · SVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,650

Underlying: Common Stock · 27,650 shares

Expires not disclosed

F2 · derivative.exercise_date: The performance stock units (PSUs) vest in full upon tentative approval by the U.S. Food and Drug Administration of the New Drug Application for LIQ861. Each PSU represents a contingent right to receive one share of common stock of the issuer.

F2 · derivative.expiration_date: The performance stock units (PSUs) vest in full upon tentative approval by the U.S. Food and Drug Administration of the New Drug Application for LIQ861. Each PSU represents a contingent right to receive one share of common stock of the issuer.

SEC source: 0001104659-21-005987 · tm213622-4_4seq1.xml · derivative · entry 1

Krawchick Florina · CIK 0001783634 · SVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,300

Underlying: Common Stock · 55,300 shares

Expires 2031-01-19

F1 · derivative.exercise_date: The option vests in equal monthly installments over a four-year period, becoming fully vested on January 19, 2025.

SEC source: 0001104659-21-005983 · tm213622d2_4.xml · derivative · entry 2

Moomaw Scott · CIK 0001832592 · SVP, Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,650

Underlying: Common Stock · 7,650 shares

Expires not disclosed

F2 · derivative.exercise_date: The performance stock units (PSUs) vest in full upon tentative approval by the U.S. Food and Drug Administration of the New Drug Application for LIQ861. Each PSU represents a contingent right to receive one share of common stock of the issuer.

F2 · derivative.expiration_date: The performance stock units (PSUs) vest in full upon tentative approval by the U.S. Food and Drug Administration of the New Drug Application for LIQ861. Each PSU represents a contingent right to receive one share of common stock of the issuer.

SEC source: 0001104659-21-005983 · tm213622d2_4.xml · derivative · entry 1

Moomaw Scott · CIK 0001832592 · SVP, Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,300

Underlying: Common Stock · 15,300 shares

Expires 2031-01-19

F1 · derivative.exercise_date: The option vests in equal monthly installments over a four-year period, becoming fully vested on January 19, 2025.

SEC source: 0001578563-21-000005 · primary_doc.xml · nonDerivative · entry 1

Eshelman Ventures, LLC · CIK 0001706673 · 10% owner

ESHELMAN FREDRIC N · CIK 0001033409 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,964,314

F1 · price: This transaction was executed in multiple trades at prices ranging from $2.95 to $3.01. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the trades were effected.

F2 · ownership.direct: The securities reported as directly beneficially owned by the Reporting Person may be deemed to be indirectly beneficially owned by Dr. Eshelman, who is the manager of the Reporting Person.

SEC source: 0001578563-21-000004 · primary_doc.xml · nonDerivative · entry 1

Eshelman Ventures, LLC · CIK 0001706673 · 10% owner

ESHELMAN FREDRIC N · CIK 0001033409 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,058,149

F1 · price: This transaction was executed in multiple trades at prices ranging from $3.00 to $3.03. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the trades were effected.

F2 · ownership.direct: The securities reported as directly beneficially owned by the Reporting Person may be deemed to be indirectly beneficially owned by Dr. Eshelman, who is the manager of the Reporting Person.

SEC source: 0001578563-21-000003 · primary_doc.xml · nonDerivative · entry 2

Eshelman Ventures, LLC · CIK 0001706673 · 10% owner

ESHELMAN FREDRIC N · CIK 0001033409 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,085,149

F3 · price: This transaction was executed in multiple trades at prices ranging from $3.00 to $3.04. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the trades were effected.

F2 · ownership.direct: The securities reported as directly beneficially owned by the Reporting Person may be deemed to be indirectly beneficially owned by Dr. Eshelman, who is the manager of the Reporting Person.

SEC source: 0001578563-21-000003 · primary_doc.xml · nonDerivative · entry 1

Eshelman Ventures, LLC · CIK 0001706673 · 10% owner

ESHELMAN FREDRIC N · CIK 0001033409 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,119,615

F1 · price: This transaction was executed in multiple trades at prices ranging from $3.05 to $3.07. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the trades were effected.

F2 · ownership.direct: The securities reported as directly beneficially owned by the Reporting Person may be deemed to be indirectly beneficially owned by Dr. Eshelman, who is the manager of the Reporting Person.

SEC source: 0001578563-21-000002 · primary_doc.xml · nonDerivative · entry 2

Eshelman Ventures, LLC · CIK 0001706673 · 10% owner

ESHELMAN FREDRIC N · CIK 0001033409 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,123,008

F3 · price: This transaction was executed in multiple trades at prices ranging from $3.05 to $3.12. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the trades were effected.

F2 · ownership.direct: The securities reported as directly beneficially owned by the Reporting Person may be deemed to be indirectly beneficially owned by Dr. Eshelman, who is the manager of the Reporting Person.

SEC source: 0001578563-21-000002 · primary_doc.xml · nonDerivative · entry 1

Eshelman Ventures, LLC · CIK 0001706673 · 10% owner

ESHELMAN FREDRIC N · CIK 0001033409 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,222,343

F1 · price: This transaction was executed in multiple trades at prices ranging from $3.05 to $3.055. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the trades were effected.

F2 · ownership.direct: The securities reported as directly beneficially owned by the Reporting Person may be deemed to be indirectly beneficially owned by Dr. Eshelman, who is the manager of the Reporting Person.

SEC source: 0001578563-21-000001 · primary_doc.xml · nonDerivative · entry 2

Eshelman Ventures, LLC · CIK 0001706673 · 10% owner

ESHELMAN FREDRIC N · CIK 0001033409 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,235,867

F3 · price: This transaction was executed in multiple trades at prices ranging from $3.05 to $3.105. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the trades were effected.

F2 · ownership.direct: The securities reported as directly beneficially owned by the Reporting Person may be deemed to be indirectly beneficially owned by Dr. Eshelman, who is the manager of the Reporting Person.

SEC source: 0001578563-21-000001 · primary_doc.xml · nonDerivative · entry 1

Eshelman Ventures, LLC · CIK 0001706673 · 10% owner

ESHELMAN FREDRIC N · CIK 0001033409 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,307,769

F1 · price: This transaction was executed in multiple trades at prices ranging from $3.05 to $3.205. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the trades were effected.

F2 · ownership.direct: The securities reported as directly beneficially owned by the Reporting Person may be deemed to be indirectly beneficially owned by Dr. Eshelman, who is the manager of the Reporting Person.

SEC source: 0001578563-20-000039 · primary_doc.xml · nonDerivative · entry 1

Eshelman Ventures, LLC · CIK 0001706673 · 10% owner

ESHELMAN FREDRIC N · CIK 0001033409 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,450,588

F1 · price: This transaction was executed in multiple trades at prices ranging from $3.13 to $3.15. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the trades were effected.

F2 · ownership.direct: The securities reported as directly beneficially owned by the Reporting Person may be deemed to be indirectly beneficially owned by Dr. Eshelman, who is the manager of the Reporting Person.

SEC source: 0001578563-20-000038 · primary_doc.xml · nonDerivative · entry 2

Eshelman Ventures, LLC · CIK 0001706673 · 10% owner

ESHELMAN FREDRIC N · CIK 0001033409 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,458,537

F2 · ownership.direct: The securities reported as directly beneficially owned by the Reporting Person may be deemed to be indirectly beneficially owned by Dr. Eshelman, who is the manager of the Reporting Person.

SEC source: 0001578563-20-000038 · primary_doc.xml · nonDerivative · entry 1

Eshelman Ventures, LLC · CIK 0001706673 · 10% owner

ESHELMAN FREDRIC N · CIK 0001033409 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,510,443

F1 · price: This transaction was executed in multiple trades at prices ranging from $3.13 to $3.165. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the trades were effected.

F2 · ownership.direct: The securities reported as directly beneficially owned by the Reporting Person may be deemed to be indirectly beneficially owned by Dr. Eshelman, who is the manager of the Reporting Person.

SEC source: 0001104659-20-135897 · tm2037368-4_4.xml · derivative · entry 1

deGoa Damian · CIK 0001836165 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,000,000

Underlying: Common Stock · 2,000,000 shares

Expires 2030-12-14

F1 · derivative.exercise_date: The option vests over a four-year period with 25% of the shares of common stock underlying the option vesting on the one-year anniversary of the grant date and the remaining 75% of the shares of common stock underlying the option vesting in equal monthly installments thereafter, becoming fully vested on December 14, 2024; provided, however, that, notwithstanding the foregoing vesting schedule, (x) 25% of the shares of common stock underlying the option will vest upon U.S. Food and Drug Administration tentative approval of the issuer's New Drug Application for LIQ861 prior to June 30, 2022 and

F2 · derivative.exercise_date: (y) 25% of the shares of common stock underlying the option will vest upon commercial availability of subcutaneous treprostinil with cartridge supplies sufficient to support the market for one year prior to December 31, 2021; provided, further, that upon a Change in Control (as defined in the accompanying Nonstatutory Stock Option Agreement) 100% of the unvested portion of the option shall become vested and exercisable as of the date of the Change in Control, provided that Mr. deGoa is actively employed with Liquidia Technologies, Inc. on such date.

SEC source: 0001578563-20-000036 · primary_doc.xml · nonDerivative · entry 1

Eshelman Ventures, LLC · CIK 0001706673 · 10% owner

ESHELMAN FREDRIC N · CIK 0001033409 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,563,752

F1 · ownership.direct: The securities reported as directly beneficially owned by the Reporting Person may be deemed to be indirectly beneficially owned by Dr. Eshelman, who is the manager of the Reporting Person.

SEC source: 0001578563-20-000035 · primary_doc.xml · nonDerivative · entry 2

Eshelman Ventures, LLC · CIK 0001706673 · 10% owner

ESHELMAN FREDRIC N · CIK 0001033409 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,570,169

F1 · ownership.direct: The securities reported as directly beneficially owned by the Reporting Person may be deemed to be indirectly beneficially owned by the Dr. Eshelman, who is the manager of the Reporting Person.

SEC source: 0001104659-20-130857 · a4.xml · derivative · entry 1

Kaseta Michael · CIK 0001724346 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 230,000

Underlying: Common Stock · 230,000 shares

Expires 2030-11-30

F1 · derivative.exercise_date: The option vests over a four-year period with 25% of the shares of common stock underlying the option vesting on the one-year anniversary of the grant date and the remaining 75% of the shares of common stock underlying the option vesting in equal monthly installments thereafter, becoming fully vested on November 30, 2024.

SEC source: 0001578563-20-000035 · primary_doc.xml · nonDerivative · entry 1

Eshelman Ventures, LLC · CIK 0001706673 · 10% owner

ESHELMAN FREDRIC N · CIK 0001033409 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,570,369

F1 · ownership.direct: The securities reported as directly beneficially owned by the Reporting Person may be deemed to be indirectly beneficially owned by the Dr. Eshelman, who is the manager of the Reporting Person.

SEC source: 0001578563-20-000034 · primary_doc.xml · nonDerivative · entry 4

Eshelman Ventures, LLC · CIK 0001706673 · 10% owner

ESHELMAN FREDRIC N · CIK 0001033409 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,570,569

F2 · ownership.direct: The securities reported as directly beneficially owned by the Reporting Person may be deemed to be indirectly beneficially owned by the Dr. Eshelman, who is the manager of the Reporting Person.

SEC source: 0001578563-20-000034 · primary_doc.xml · nonDerivative · entry 3

Eshelman Ventures, LLC · CIK 0001706673 · 10% owner

ESHELMAN FREDRIC N · CIK 0001033409 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,587,933

F4 · price: This transaction was executed in multiple trades at prices ranging from $3.13 to $3.235. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the trades were effected.

F2 · ownership.direct: The securities reported as directly beneficially owned by the Reporting Person may be deemed to be indirectly beneficially owned by the Dr. Eshelman, who is the manager of the Reporting Person.

SEC source: 0001578563-20-000034 · primary_doc.xml · nonDerivative · entry 2

Eshelman Ventures, LLC · CIK 0001706673 · 10% owner

ESHELMAN FREDRIC N · CIK 0001033409 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,871,398

F3 · price: This transaction was executed in multiple trades at prices ranging from $3.12 to $3.26. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the trades were effected.

F2 · ownership.direct: The securities reported as directly beneficially owned by the Reporting Person may be deemed to be indirectly beneficially owned by the Dr. Eshelman, who is the manager of the Reporting Person.